Collaboration Agreements (Tables)

12 Months Ended

Dec. 31, 2022

Research and Development [Abstract]

Schedule of Disaggregation of Revenue

The following table summarizes grant revenue for the periods presented (in millions):

	Years Ended December 31,
	2022		2021		2020
BARDA	$	372	$	713	$	522
Other grant revenue	16		22		7
Total grant revenue	$	388	$	735	$	529

The following table summarizes our total consolidated net revenue from our strategic collaborators for the periods presented (in millions):

	Years Ended December 31,
Collaboration Revenue by Strategic Collaborator:	2022		2021		2020
Merck	$	309	$	23	$	26
AstraZeneca	80		7		33
Vertex	48		26		15
Other	3		5		—
Total collaboration revenue	$	440	$	61	$	74

Schedule of Changes in Balances of Receivables and Contract Liabilities

The following table presents changes in the balances of our receivables and contract liabilities related to our strategic collaboration agreements during the year ended December 31, 2022 (in millions):

	December 31, 2021		Additions		Deductions		December 31, 2022
Contract Assets:
Accounts receivable	$	9	$	318	$	(310)	$	17
Contract Liabilities:
Deferred revenue	$	204	$	16	$	(139)	$	81

The following table summarizes the activities in deferred revenue during the year ended December 31, 2022 (in millions):

	December 31, 2021		Additions		Deductions		December 31, 2022
Product sales	$	6,658	$	2,510	$	(6,542)	$	2,626
Grant revenue	6		—		(2)		4
Collaboration revenue	204		16		(139)		81
Total deferred revenue	$	6,868	$	2,526	$	(6,683)	$	2,711